CG Oncology

CG Oncology is a clinical-stage biopharmaceutical company dedicated to developing innovative bladder-sparing therapies for patients with bladder cancer. Their lead product candidate, cretostimogene grenadenorepvec, is an oncolytic immunotherapy designed to selectively replicate within tumor cells and stimulate an anti-tumor immune response. CG Oncology has multiple clinical trials underway, including Phase 3 studies for both high-risk and intermediate-risk Non-Muscle Invasive Bladder Cancer (NMIBC). They are also investigating the combination of cretostimogene with checkpoint inhibitors for high-risk NMIBC.

CG Oncology emphasizes a patient-centric approach, evidenced by their commitment to developing bladder-sparing treatments and their dedication to supporting patient well-being. Their company culture emphasizes perseverance, integrity, collaboration, well-being, patient-centered focus, and innovation. The company is actively seeking to build a diverse and inclusive team that shares their vision for a future where urologic cancer patients can benefit from their innovative immunotherapies.

CG Oncology does not explicitly state information about job flexibility on their website, nor in any of the job postings provided. Therefore, it is not possible to provide a description of the job flexibility provided by the company.

CG Oncology offers highly competitive and comprehensive Total Rewards, including competitive salaries, annual performance and merit reviews, annual performance bonuses, equity, and special recognition programs. In addition, they provide a variety of Well-Being Benefits such as retirement plans, health insurance (medical, dental, vision), company holidays, and fully remove work environment and rest and recharge benefits.

CG Oncology is a late-stage clinical biopharmaceutical company dedicated to developing and commercializing innovative bladder-sparing therapies for patients with bladder cancer. Their mission is to create a world where patients suffering from urologic cancers can benefit from their immunotherapies, enabling them to live with dignity and enjoy a higher quality of life. Their primary focus is on developing treatments that can potentially prevent the need for bladder removal surgery.

CG Oncology fosters a culture of perseverance, integrity, collaboration, and well-being. They emphasize a strong work ethic and commitment to achieving excellence, while also prioritizing a healthy work-life balance and fostering a respectful and inclusive environment. This culture is built on the belief that their success is a collective effort, involving strong partnerships with patients, academics, industry leaders, and investors.

CG Oncology is committed to creating a diverse, equitable, and inclusive work environment. They are focused on building a community of talented individuals who share their vision, mission, and values, regardless of race, color, religion, sex, sexual orientation, gender identity, national origin, veteran, or disability status. CG Oncology recognizes the underrepresentation of BIPOC, non-binary, and female individuals in the biotechnology space and endeavors to make hiring decisions that support a diverse and sustainable team.